Successful incorporation of imaging into a clinical trial requires careful consideration of the patient population and the patient experience. Study sponsors, like Pfizer, should carefully consider how a study can be designed to minimize patient burden, while still collecting essential information about the disease status. In this webinar, the featured speakers will discuss the considerations for incorporating muscle magnetic resonance imaging (MRI) assessments into Duchenne Muscular Dystrophy (DMD) clinical trials. In addition, the featured speakers will review the value of muscle MRI to understand potential therapies. The speakers will also discuss the patient experience with MRI, and why to consider incorporating MRI into DMD clinical trials.
Parent Project Muscular Dystrophy (PPMD), a patient advocacy group fighting to end Duchenne, seeks to accelerate drug development to ensure patients can receive beneficial therapies. Supporting novel outcome measures, such as the inclusion of MRI, can enhance the design of clinical trials to benefit patients. The featured speakers will discuss the desire of patient communities for better outcome measures to evaluate potential therapies.
AMRA Medical’s experience in MRI for clinical research has been growing for over a decade. Focusing on patient needs in the scanner and the overall imaging demands, are critical for a successful study. The most precious part of any study is the participants themselves and their comfort. AMRA will address an approach to MRI protocols that are short and patient friendly.
Join this webinar with the expertise of Pfizer, PPMD, parents of patients and AMRA Medical. Attendees will get an insider’s view on MRI for DMD clinical trials.
